325 related articles for article (PubMed ID: 25127039)
1. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
Perez-Carbonell L; Balaguer F; Toiyama Y; Egoavil C; Rojas E; Guarinos C; Andreu M; Llor X; Castells A; Jover R; Boland CR; Goel A
PLoS One; 2014; 9(8):e104285. PubMed ID: 25127039
[TBL] [Abstract][Full Text] [Related]
2. Clinical Relevance of Plasma DNA Methylation in Colorectal Cancer Patients Identified by Using a Genome-Wide High-Resolution Array.
Lin PC; Lin JK; Lin CH; Lin HH; Yang SH; Jiang JK; Chen WS; Chou CC; Tsai SF; Chang SC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1419-27. PubMed ID: 25472652
[TBL] [Abstract][Full Text] [Related]
3. IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma.
Kumar A; Singh P; Pandey A; Gosipatala SB
Mol Biol Rep; 2020 Sep; 47(9):6919-6927. PubMed ID: 32929656
[TBL] [Abstract][Full Text] [Related]
4. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
[TBL] [Abstract][Full Text] [Related]
5. Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.
Draht MX; Smits KM; Tournier B; Jooste V; Chapusot C; Carvalho B; Cleven AH; Derks S; Wouters KA; Belt EJ; Stockmann HB; Bril H; Weijenberg MP; van den Brandt PA; de Bruïne AP; Herman JG; Meijer GA; Piard F; Melotte V; van Engeland M
Mol Oncol; 2014 May; 8(3):679-88. PubMed ID: 24560444
[TBL] [Abstract][Full Text] [Related]
6. A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway.
Freitas M; Ferreira F; Carvalho S; Silva F; Lopes P; Antunes L; Salta S; Diniz F; Santos LL; Videira JF; Henrique R; Jerónimo C
J Transl Med; 2018 Feb; 16(1):45. PubMed ID: 29486770
[TBL] [Abstract][Full Text] [Related]
7. NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy.
Chang SY; Kuo CC; Wu CC; Hsiao CW; Hu JM; Hsu CH; Chou YC; Shih YL; Lin YW
Genes Chromosomes Cancer; 2018 May; 57(5):268-277. PubMed ID: 29363224
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
[TBL] [Abstract][Full Text] [Related]
9. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53.
Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS; Ogino S
Neoplasia; 2007 Dec; 9(12):1091-8. PubMed ID: 18084616
[TBL] [Abstract][Full Text] [Related]
10. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
[TBL] [Abstract][Full Text] [Related]
11. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
12. Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.
Murcia O; Juárez M; Hernández-Illán E; Egoavil C; Giner-Calabuig M; Rodríguez-Soler M; Jover R
World J Gastroenterol; 2016 Apr; 22(13):3516-30. PubMed ID: 27053844
[TBL] [Abstract][Full Text] [Related]
13. A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival.
Jia M; Zhang Y; Jansen L; Walter V; Edelmann D; Gündert M; Tagscherer KE; Roth W; Bewerunge-Hudler M; Herpel E; Kloor M; Ulrich A; Burwinkel B; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
Clin Epigenetics; 2019 Jul; 11(1):109. PubMed ID: 31340858
[TBL] [Abstract][Full Text] [Related]
14. Methylator phenotype in colorectal cancer: A prognostic factor or not?
Gallois C; Laurent-Puig P; Taieb J
Crit Rev Oncol Hematol; 2016 Mar; 99():74-80. PubMed ID: 26702883
[TBL] [Abstract][Full Text] [Related]
15. Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation.
Wierzbicki PM; Adrych K; Kartanowicz D; Stanislawowski M; Kowalczyk A; Godlewski J; Skwierz-Bogdanska I; Celinski K; Gach T; Kulig J; Korybalski B; Kmiec Z
World J Gastroenterol; 2013 Jul; 19(27):4363-73. PubMed ID: 23885148
[TBL] [Abstract][Full Text] [Related]
16. Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients.
Takane K; Midorikawa Y; Yagi K; Sakai A; Aburatani H; Takayama T; Kaneda A
Cancer Med; 2014 Oct; 3(5):1235-45. PubMed ID: 24861485
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel.
Vilkin A; Niv Y; Nagasaka T; Morgenstern S; Levi Z; Fireman Z; Fuerst F; Goel A; Boland CR
Cancer; 2009 Feb; 115(4):760-9. PubMed ID: 19127559
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
[TBL] [Abstract][Full Text] [Related]
19. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers.
Park HW; Kang HC; Kim IJ; Jang SG; Kim K; Yoon HJ; Jeong SY; Park JG
Int J Cancer; 2007 Jan; 120(1):7-12. PubMed ID: 17013898
[TBL] [Abstract][Full Text] [Related]
20. p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer.
Wettergren Y; Odin E; Nilsson S; Carlsson G; Gustavsson B
Mol Med; 2008; 14(7-8):412-21. PubMed ID: 18418463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
